Clin cancer res: Endometrial-like ovarian cancer or a treatment strategy for endometrial cancer may be used.

The prognosis of endometrial-like ovarian cancer (ENOC) is usually better than other ovarian cancers.
Despite this, the current patient treatment is still followed by a "one size fits all" approach.
even if the tumor is stratified in stages, personalized treatment is still difficult to achieve.
In view of the many same clinical and molecular characteristics of ENOC and its endometrial similarities, Kremer and others attempted to study TCGA-induced endometrial cancer (EC) molecular disposition in the ENOC queue.
511 ENOC tumors were divided into four EC-induced molecular subtypes through immunohistization and mutant biomarkers: low-risk POLE mutant (POLEmut), medium-risk mismatch repair defect type (MMRd), high-risk p53 abnormality (p53abn) and medium risk (NSMP) without special molecules.
survival analysis of established clinical pathology and subtype specific characteristics.
cases of POLEmut, MMRd, p53abn and NSMP were 3.5%, 13.7%, 9.6% and 73.2% respectively, with varying prognosis (p.lt;0.001) and survival similar to EC.
NSMP, MMRd, p53abn and POLEmut median OS were 18.1 years, 12.3 years, 4.7 years and not reached, respectively.
in multivariate analysis, subtypes were not associated with staging, grading, and residual diseases.
Summary: EC-inspired molecular classifications provide independent prognosis information in ENOC.
the results of this study support the study of specific management recommendations for molecular subtypes in ENOC patients; the similarity between eNOC and EC
indicates that ENOC patients may benefit from EC's management strategy.
.